This report provides information on the therapeutic development for Rectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

1. Rectal Cancer - Pipeline Review, Q3 2011
Report Summary
Global Markets Direct’s, 'Rectal Cancer - Pipeline Review, Q3 2011', provides an
overview of the Rectal Cancer therapeutic pipeline. This report provides information
on the therapeutic development for Rectal Cancer, complete with latest updates,
and special features on late-stage and discontinued projects. It also reviews key
players involved in the therapeutic development for Rectal Cancer. 'Rectal Cancer -
Pipeline Review, Q3 2011' is built using data and information sourced from Global
Markets Direct’s proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from company/university sites
and industry-specific third party sources, put together by Global Markets Direct’s
team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
* A snapshot of the global therapeutic scenario for Rectal Cancer.
* A review of the Rectal Cancer products under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources.
* Coverage of products based on various stages of development ranging from
discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
* Coverage of the Rectal Cancer pipeline on the basis of therapeutic class, route of
administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description,
mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Browse All Pharmaceuticals Market Research Reports
Reasons to buy
* Identify and understand important and diverse types of therapeutics under
development for Rectal Cancer.
* Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most
promising pipeline.

2. * Devise corrective measures for pipeline projects by understanding Rectal Cancer
pipeline depth and focus of Rectal Cancer therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Rectal Cancer Overview 6
Therapeutics Development 7
Rectal Cancer Therapeutics under Development by Companies 9
Rectal Cancer Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 17
Mid Clinical Stage Products 18
Early Clinical Stage Products 19
Pre-Clinical Stage Products 20
Rectal Cancer Therapeutics - Products under Development by Companies 21
Rectal Cancer Therapeutics - Products under Investigation by Universities/Institutes
22
Companies Involved in Rectal Cancer Therapeutics Development 28
Rectal Cancer - Therapeutics Assessment 32
Late Stage Drug Profiles 38
Rectal Cancer Therapeutics – Drug Profile Updates 193
Rectal Cancer Therapeutics - Discontinued Products 195
Appendix 196
Methodology 196
Contact Us 197
Disclaimer 197
List of Tables
Number of Products Under Development for Rectal Cancer, Q3 2011 16
Products under Development for Rectal Cancer – Comparative Analysis, Q3 2011 17
Number of Products under Development by Companies, Q3 2011 19
Number of Products under Investigation by Universities/Institutes, Q3 2011 21
Number of Products under Investigation by Universities/Institutes, Q3 2011 22
Number of Products under Investigation by Universities/Institutes, Q3 2011 23
Number of Products under Investigation by Universities/Institutes, Q3 2011 24

3. Number of Products under Investigation by Universities/Institutes, Q3 2011 25
Comparative Analysis by Late Stage Development, Q3 2011 26
Comparative Analysis by Mid Clinical Stage Development, Q3 2011 27
Comparative Analysis by Early Clinical Stage Development, Q3 2011 28
Comparative Analysis by Pre-Clinical Stage Development, Q3 2011 29
Products under Development by Companies, Q3 2011 30
Products under Investigation by Universities/Institutes, Q3 2011 31
Products under Investigation by Universities/Institutes, Q3 2011 32
Products under Investigation by Universities/Institutes, Q3 2011 33
Products under Investigation by Universities/Institutes, Q3 2011 34
Products under Investigation by Universities/Institutes, Q3 2011 35
Products under Investigation by Universities/Institutes, Q3 2011 36
Sanofi-Aventis, 2011 37
Eli Lilly and Company, 2011 37
GenVec, Inc., 2011 38
Merck & Co., Inc., 2011 38
Celltrion, Inc., 2011 39
ImClone Systems Incorporated, 2011 39
Oncolytics Biotech Inc., 2011 40
Globeimmune, Inc., 2011 40
Assessment by Monotherapy Products, Q3 2011 41
Assessment by Combination Products 42
Assessment by Stage and Route of Administration, Q3 2011 44
Assessment by Molecule Type, Q3 2011 46
Rectal Cancer Therapeutics – Drug Profile Updates 202
Discontinued Products 204
List of Figures
Number of Products under Development for Rectal Cancer, Q3 2011 16
Products under Development for Rectal Cancer – Comparative Analysis, Q3 2011 17
Products under Development by Companies, Q3 2011 18
Products under Investigation by Universities/Institutes, Q3 2011 20
Late Stage Products, Q3 2011 26
Mid Clinical Stage Products, Q3 2011 27
Early Clinical Stage Products, Q3 2011 28
Pre-Clinical Stage Products, Q3 2011 29
Assessment by Monotherapy Products, Q3 2011 41
Assessment by Combination Products, Q3 2011 42
Assessment by Route of Administration, Q3 2011 43
Assessment by Stage and Route of Administration, Q3 2011 44
Assessment by Molecule Type, Q3 2011 45
Assessment by Stage and Molecule Type, Q3 2011 46

4. About Us:
ReportsnReports is an online library of over 100,000+ market research reports and
in-depth market research studies & analysis of over 5000 micro markets. We
provide 24/7 online and offline support to our customers. Get in touch with us for
your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page:
http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog